|A unique collection of 81 Cardioprotective natural compounds for high throughput screening (HTS) and high content screening (HCS).|
|Catalog No:||Bb1313|| Cardioprotective Compound Library
|Size:||1mg/well * 81 Compounds|
2mg/well * 81 Compounds
1. Asperosaponin VI exhibits a significant induction of proliferation, differentiation and mineralization in MC3T3-E1 and primary osteoblastic cells, it may induce osteoblast maturation and differentiation, and then increase bone formation via increasing BMP-2 synthesis, and activating p38 and ERK1/2.
2. Asperosaponin VI plays protective roles on acute myocardial infarction in rats.
3. Asperosaponin VI has protective effect against hypoxia-induced cardiomyocytes apoptosis probably by activating the PI3K/Akt and CREB pathways.
1. Bilobalide can protect PC12 cells from A beta 25-35-induced cytotoxicity, it dose-dependently attenuates the cytotoxic effect of A beta 25-35.
2. Bilobalide exerts protective and trophic effects on neurons, the PI3K/Akt pathway may be involved in the protective effects of bilobalide.
3. Bilobalide possesses anticonvulsant activity, the anticonvulsant effect is due to elevation of GABA levels, possibly through potentiation of glutamic acid decarboxylase activity and enhancement of the protein amount of 67 kDa glutamic acid decarboxylase by bilobalide.
4. PAF(platelet-activating factor) and its receptor may be involved in the cellular response of cardiomyocytes to hypoxia and that bilobalide may interact with this receptor to exert its cardioprotective effects.
5. Bilobalide and its derivatives( contain trilactone structure) have insecticidal activity.
1. Madecassoside has antioxidant and anti-inflammatory activities, it can effectively alleviate inflammatory response on CIA, and anti-inflammatory effects of MA can be attributed, at least partially, to the inhibition of pro-inflammatory mediators, including COX-2 expression, PGE2 production, TNF-αand IL-6 levels and the up-regulation anti-inflammatory molecule IL-10.
2. Madecassoside is a mechanism-based inhibitor of CYP2C19 and CYP3A4, suggests that madecassoside can cause drug-drug interactions via inhibition of CYP2C19 and CYP3A4.
3. Madecassoside has significant wound-healing activity and is one of the major reasons for the use of C. ASIATICA herbs in the successful treatment of burn injury, the effect of madecassoside on wound healing may involve several mechanisms including antioxidative activity, collagen synthesis and angiogenesis.
4. Madecassoside has the protective effect on myocardial ischemia-reperfusion injury, this protection ability possibly due to its anti-lipid peroxidation, anti-inflammation and anti-apoptosis function and the enhancement of SOD activity.
5. Madecassoside can suppress LPS-induced TNF-αproduction in cardiomyocytes through inhibition of ERK, p38, and NF-κB activity, it may have cardioprotective effects in LPS-mediated .
6. Madecassoside is neuroprotective and may be useful in reducing the damage caused by stroke.
|CFN99950||Hydroxysafflor yellow A
1. Hydroxysafflor yellow A can effectively protect the liver of rats from long-term alcohol injury, which relates with the enhanced antioxidant capacity of liver tissues and inhibition of TGF-β1 expression.
2. Hydroxysafflor yellow A attenuates inflammatory response in ALI mice through inhibition of TLR 4-dependent signaling pathways.
3. Hydroxysafflor yellow A shows inhibitory action on adipogenesis, which may be due to the promotion of lipolytic-specific enzyme HSL expression by increasing HSL promoter activity.
4. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice.
5. Hydroxysafflor yellow A can provide protection to H9c2 cardiomyocytes against A/R-induced apoptosis, and this protective effect largely depends on the upregulation of HO-1 expression through the PI3K/Akt/Nrf2 signaling pathway.
6. Hydroxysafflor yellow A suppresses inflammatory responses of BV2 microglia after oxygen-glucose deprivation, which is probably associated with the inhibition of the NF-κB signaling pathway and phosphorylation of p38.
1. Pseudoginsenoside F11(PF11) possesses significant neuroprotective activity, PF11exerts anti-neuroinflammatory effects on LPS-activated microglial cells by inhibiting TLR4-mediated TAK1/IKK/NF-NF-kappaB, MAPKs and Akt signaling pathways.
2. Pseudoginoside F11 antagonizes the development of analgesia tolerance to morphine, it has antagonistic effect on the various actions of morphine.
3. Pseudoginoside F11 may block the development of morphine-induced behavioral sensitization via its effect, at least partially, on the glutamatergic system in the mPFC.
4. Pseudoginsenoside F11 is a novel partial PPAR γ agonist, can promote adiponectin oligomerization and secretion in 3T3-L1 adipocytes and inhibit obesity-linked phosphorylation of PPAR γ at Ser-273 by Cdk5.
5. Pseudoginsenoside F11 demonstrates to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice, it may serve as a potential therapeutic agent for the treatment of AD.